MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager

Statement of Purpose
Guidelines for Authors
Editorial Board

Recent Issues

February 2005


Letter to the Editor

Act Now: Raising Awareness of DVT

Efforts are under way to educate health care professionals and the public about deep vein thrombosis, a common, potentially fatal disease.
James Groce III, PharmD, CACP

A Pharmacoeconomic Model for Making Value-Based Decisions About Serotonin Reuptake Inhibitors

The authors discuss formulary considerations for the largest therapeutic class of prescription drugs and their efficacy in treating depression and anxiety.
Patrick W. Sullivan, PhD; Robert Valuck, PhD, RPh; Diana I. Brixner, PhD; Edward P. Armstrong, PharmD

Meeting Highlights

46th Annual Meeting of the American Society of Hematology

Dr. Prescott reviews the latest developments in treatments for malignant and nonmalignant hematological diseases.
Lawrence M. Prescott, PhD

Continuing Education Credit

An Evidence-Based Summary of Insulin Analogues

The authors compare and contrast the safety and efficacy of the newer insulin products—insulin aspart (NovoLog®), lispro (Humalog®), and glargine (Lantus®)—with existing human insulin (e.g., Humulin®, Novolin®).
Bethany A. Fedutes, PharmD, Amy Calabrese Donihi, PharmD, BCPS, Colleen M. Culley, PharmD, BCPS, Bryan J. McCreery, PharmD Candidate, and Nicole T. Ansani, PharmD



Who Will Choose Your Medications?

David Nash, MD, MBA, discusses the possibility of limited choices of medications for physicians and the public under the new Medicare drug benefit.
David B. Nash, MD, MBA

Prescription: Washington

Congress Whets Its Carving Knife: Deep Cuts for Medicaid Drug Reimbursement

Stephen Barlas anticipates the likelihood of decreased Medicaid reimbursement to pharmacies for prescription drugs.
Stephen Barlas

Medication Errors

Admitting “Overflow” Patients to Units Without Proper Expertise Invites Errors

Matthew Grissinger, RPh, FASCP, discusses the risk of errors when staff members are not adequately informed about the potential dangers of glycoprotein IIb/IIIa inhibitors.
Matthew Grissinger, RPh, FASCP

New Drugs/Drug News/New Medical Devices

P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.

Drug Forecast

Ximelagatran (Exanta™): A Product Review and Update

Drs. Hilas and Marzella review ximelagatran (Exanta™), an oral direct thrombin inhibitor.
Olga Hilas, BS, PharmD, and Nino Marzella, BS, PharmD